LCZ696 - CAS 936623-90-4
Catalog number:
936623-90-4
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C96H120N12Na6O21
Molecular Weight:
1916.02
COA:
Inquire
Targets:
Angiotensin Receptor
Description:
LCZ696 is a potent ARNi inhibitor and an investigational drug to treat heart failure. Chemically, LCZ696 is a mixture of valsartan and sacubitril in a 1:1 molar ratio.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
MSDS:
Inquire
1.Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction.
Kobalava Z1, Kotovskaya Y1, Averkov O1, Pavlikova E1, Moiseev V1, Albrecht D2, Chandra P3, Ayalasomayajula S3, Prescott MF4, Pal P5, Langenickel TH2, Jordaan P2, Rajman I2. Cardiovasc Ther. 2016 Mar 14. doi: 10.1111/1755-5922.12183. [Epub ahead of print]
AIMS: Concomitant renin-angiotensin-aldosterone system blockade and natriuretic peptide system enhancement may provide unique therapeutic benefits to patients with heart failure and reduced ejection fraction (HFrEF). This study assessed the pharmacodynamics and pharmacokinetics of LCZ696 in patients with HFrEF.
2.Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.
Gan L1, Jiang X2, Mendonza A1, Swan T1, Reynolds C2, Nguyen J2, Pal P3, Neelakantham S3, Dahlke M4, Langenickel T4, Rajman I4, Akahori M5, Zhou W2, Rebello S2, Sunkara G2. Clin Pharmacol Drug Dev. 2016 Jan;5(1):27-39. doi: 10.1002/cpdd.181. Epub 2015 Nov 4.
LCZ696 is a novel angiotensin receptor neprilysin inhibitor in development for the treatment of cardiovascular diseases. Here, we assessed the potential for pharmacokinetic drug-drug interaction of LCZ696 (400 mg, single dose or once daily [q.d.]) when co-administered with omeprazole 40 mg q.d. (n = 28) or metformin 1000 mg q.d. (n = 27) or levonorgestrel-ethinyl estradiol 150/30 μg single dose (n = 24) in three separate open-label, single-sequence studies in healthy subjects. Pharmacokinetic parameters of LCZ696 analytes (sacubitril, LBQ657, and valsartan), metformin, and levonorgestrel-ethinyl estradiol were assessed. Omeprazole did not alter the AUCinf of sacubitril and pharmacokinetics of LBQ657; however, 7% decrease in the Cmax of sacubitril, and 11% and 13% decreases in AUCinf and Cmax of valsartan were observed. Co-administration of LCZ696 with metformin had no significant effect on the pharmacokinetics of LBQ657 and valsartan; however, AUCtau,ss and Cmax,ss of metformin were decreased by 23%.
3.Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.
Langenickel TH1, Jordaan P2, Petruck J3, Kode K4, Pal P4, Vaidya S5, Chandra P6, Rajman I2. Eur J Clin Pharmacol. 2016 Apr 16. [Epub ahead of print]
PURPOSE: Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA class II-IV) and reduced ejection fraction. This study was aimed to evaluate the effect of single oral therapeutic (400 mg) and supratherapeutic (1200 mg) doses of LCZ696 on cardiac repolarization.
4.Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects.
Han Y1, Ayalasomayajula S2, Pan W1,3, Yang F1, Yuan Y4, Langenickel T5, Hinder M5, Kalluri S6, Pal P6, Sunkara G7. Eur J Drug Metab Pharmacokinet. 2016 Mar 9. [Epub ahead of print]
BACKGROUND AND OBJECTIVE: Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) and has been recently approved in several countries for the treatment of patients with heart failure and reduced ejection fraction. This was the first study conducted to characterise the pharmacokinetics of LCZ696 analytes (pro-drug sacubitril, active neprilysin inhibitor LBQ657 and valsartan) after single-dose administration of LCZ696 in healthy Chinese subjects.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Angiotensin Receptor Products


CAS 139481-59-7 Candesartan

Candesartan
(CAS: 139481-59-7)

Candesartan (10 mg/kg) inhibits the growth of engrafted tumors and reduces the microvessel density and VEGF expression in a mouse KU-19-19 xenograft model

CAS 124750-99-8 Losartan Potassium (DuP 753)

Losartan Potassium (DuP 753)
(CAS: 124750-99-8)

Losartan is an angiotensin II receptor antagonist that competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. It promotes vasodilatati...

CAS 156001-18-2 Embusartan

Embusartan
(CAS: 156001-18-2)

Embusartan, an oxopyridine derivative, has been found to be an angiotensin II receptor antagonist that was once studied against hypertension by Bayer.

CAS 247257-48-3 Fimasartan

Fimasartan
(CAS: 247257-48-3)

Fimasartan, also called as BR-A657, approved for the treatment of mild to moderate hypertension in South Korea, is a novel, non-peptide angiotensin II (Ang II) ...

AVE 0991
(CAS: 304462-19-9)

AVE 0991 is an agonist of nonpeptide Ang-(1-7) receptor Mas that has potential as a cardiovascular drug.

CAS 147403-03-0 Azilsartan Medoxomil

Azilsartan Medoxomil
(CAS: 147403-03-0)

Azilsartan (TAK-536) is an angiotensin II receptor antagonist used in the treatment of hypertension.

CAS 145216-43-9 Forasartan

Forasartan
(CAS: 145216-43-9)

Forasartan, a tetrazol derivative, has been found to be a angiotensin II receptor antagonist that could be effective against hypertension through influencing th...

CAS 114798-26-4 Losartan

Losartan
(CAS: 114798-26-4)

Losartan, an antagonist of angiotensin II receptor, could be effective in the treatment of hypertensive. IC50: 20nM.

CAS 144689-63-4 Olmesartan Medoxomil

Olmesartan Medoxomil
(CAS: 144689-63-4)

Olmesartan Medoxomil is a compound which is hydrolyzed to olmesartan that is a selective AT1 subtype angiotensin II receptor antagonist.

MK 996
(CAS: 157263-00-8)

MK-996, an imidazopyridine derivative, has been found to be an angiotensin receptor antagonist that was once developed in the treatment of hypertension by Merck...

CAS 51833-78-4 Angiotensin I/II (1-7)

Angiotensin I/II (1-7)
(CAS: 51833-78-4)

Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor, inducing vasorelaxation through release of NO and prostaglandins.

CAS 144689-24-7 Olmesartan

Olmesartan
(CAS: 144689-24-7)

Olmesartan, a synthetic imidazole derivative, is a specific angiotensin II type 1 (AT1) receptor antagonist with antihypertensive effect. hAT1 receptors: IC50 =...

Tranilast Sodium
(CAS: 104931-56-8)

Tranilast, an allergic media blocker, is effective for the treatment of asthma and is also used to treat asthma, allergic rhinitis and other allergic disorders.

BMS 183920
(CAS: 153072-33-4)

BMS 183920, a quinoline derivative, has been found to be an angiotensin II receptor antagonist that could have potential usage in antihypertensive study.

CAS 127060-75-7 CGP-42112A

CGP-42112A
(CAS: 127060-75-7)

CGP-42112A, an angiotensin AT2 receptor agonist which could probably lead to the inhibition of ATPase and contraction of aortic rings in rabbit.

CGP 48369
(CAS: 135689-23-5)

Cgp 48369 is a nonpeptide a angiotensin type 1 receptor antagonist originated by Novartis. Treatmenf for for Hypertension in Switzerland was discontinued in 199...

PD 123177
(CAS: 114785-12-5)

PD 123177 is a Nonpeptide angiotensin type 2 receptor inhibitor. In Dec 1995, Preclinical development of it for cardiovascular disorders was began in USA.

AVE 0991 sodium salt
(CAS: 306288-04-0)

AVE 0991 sodium salt, is an agonist of nonpeptide Ang-(1-7) receptor Mas that has potential as a cardiovascular drug.

CAS 145040-37-5 Candesartan Cilexetil

Candesartan Cilexetil
(CAS: 145040-37-5)

Candesartan blocks the effects of angiotensin II at the angiotensin II type 1 (AT1) receptor. Candesartan cilexetil is a prodrug that is activated to candesarta...

CAS 149690-05-1 Sacubitril sodium

Sacubitril sodium
(CAS: 149690-05-1)

Sacubitril, also known as AHU377, is a first-in-class medicine that contains a neprilysin (NEP) inhibitor (sacubitril) and an angiotensin II (Ang-II) receptor b...

Chemical Structure

CAS 936623-90-4 LCZ696

Quick Inquiry

Verification code

Featured Items